IQV vs TEM
IQV: IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2 billion de-identified patient records. TEM: Tempus AI leverages genomic sequencing, clinical data aggregation, and machine learning to deliver precision oncology diagnostics and AI-powered treatment recommendations that guide cancer patient care.
Side-by-side fundamentals
| Metric | IQV | TEM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $198.52 | $46.96 | |
| Market cap as of 2026-07-23 | $33.2B | $8.4B | |
| P/E as of 2026-07-23 | 23.98 | n/a | |
| PEG as of 2026-07-23 | 2.51 | n/a | |
| Net margin as of 2026-07-23 | +8.3% | -22.2% | IQV higher |
| Gross margin as of 2026-07-23 | +33.0% | +63.4% | TEM higher |
| Operating margin as of 2026-07-23 | +13.2% | -20.6% | IQV higher |
| ROE as of 2026-07-23 | +22.5% | -70.2% | IQV higher |
| ROA as of 2026-07-23 | +4.7% | -14.6% | IQV higher |
| Debt / equity as of 2026-07-23 | 2.55 | 2.96 | IQV lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.3% | +69.8% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +4.2% | +58.3% | TEM higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 1.20 | 2.89 | |
| 1-year return as of 2026-07-22 close | +26.8% | -23.1% | IQV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.